Search
Phenacetin
go.drugbank.com/drugs/DB03783ApprovedWithdrawnPhenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[A20298,A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage … CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract.
Ferric pyrophosphate citrate
go.drugbank.com/drugs/DB13995ApprovedFree iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. … [A31979] FPC is categorized in Japan as a second class OTC drug.
Alimemazine
go.drugbank.com/drugs/DB01246ApprovedVet approvedWithdrawnA phenothiazine derivative that is used as an antipruritic.
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The ...
Parachlorophenol
go.drugbank.com/drugs/DB13154ApprovedWithdrawnP-chlorophenol is a white crystals with a strong phenol odor. Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Sodium phosphate, dibasic
go.drugbank.com/drugs/DB14502ApprovedInvestigationalMixtures: Solution Saline Sterile Aux Phosphates